NLS Pharmaceutics (NLSP) Competitors $2.45 +0.26 (+11.87%) Closing price 04:00 PM EasternExtended Trading$2.57 +0.12 (+4.90%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. RENB, TENX, KZR, DARE, CVKD, HOTH, RNTX, LEXX, MTVA, and RLYBShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Lunai Bioworks (RENB), Tenax Therapeutics (TENX), Kezar Life Sciences (KZR), Dare Bioscience (DARE), Cadrenal Therapeutics (CVKD), Hoth Therapeutics (HOTH), Rein Therapeutics (RNTX), Lexaria Bioscience (LEXX), MetaVia (MTVA), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors Lunai Bioworks Tenax Therapeutics Kezar Life Sciences Dare Bioscience Cadrenal Therapeutics Hoth Therapeutics Rein Therapeutics Lexaria Bioscience MetaVia Rallybio NLS Pharmaceutics (NASDAQ:NLSP) and Lunai Bioworks (NASDAQ:RENB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Do institutionals & insiders hold more shares of NLSP or RENB? 71.4% of Lunai Bioworks shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, NLSP or RENB? NLS Pharmaceutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Is NLSP or RENB more profitable? NLS Pharmaceutics' return on equity of 0.00% beat Lunai Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Lunai Bioworks N/A -60.38%-47.04% Does the media prefer NLSP or RENB? In the previous week, Lunai Bioworks had 5 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 8 mentions for Lunai Bioworks and 3 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.54 beat Lunai Bioworks' score of 0.17 indicating that NLS Pharmaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lunai Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, NLSP or RENB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$1.98MN/AN/ALunai BioworksN/AN/A-$88.43M-$0.77-0.16 SummaryNLS Pharmaceutics beats Lunai Bioworks on 5 of the 8 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.88M$2.52B$5.69B$10.38BDividend YieldN/A57.80%5.78%4.70%P/E RatioN/A23.4675.6026.39Price / SalesN/A671.73519.84228.43Price / CashN/A28.1225.6730.68Price / Book-6.625.1412.826.40Net Income-$1.98M$32.92M$3.29B$276.69M7 Day Performance10.86%1.86%1.12%-0.28%1 Month Performance15.57%8.54%4.54%6.69%1 Year Performance-52.88%-6.07%68.00%27.61% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$2.45+11.9%N/A-57.9%$7.88MN/A0.006Analyst UpgradeGap UpHigh Trading VolumeRENBLunai Bioworks0.7566 of 5 stars$0.18+8.8%N/A-97.4%$30.64MN/A-0.2320Stock SplitHigh Trading VolumeTENXTenax Therapeutics2.4511 of 5 stars$6.53+1.6%$18.00+175.7%+108.0%$29.78MN/A-7.109KZRKezar Life Sciences3.6644 of 5 stars$3.90+2.1%$9.00+130.8%-32.9%$28.37M$7M-0.4060Positive NewsDAREDare Bioscience2.2108 of 5 stars$2.07+1.2%$10.00+384.3%-36.1%$27.84M$10K-0.9630Positive NewsCVKDCadrenal Therapeutics2.9787 of 5 stars$13.45+2.9%$32.00+138.0%-3.2%$27.56MN/A-1.514Insider TradeHOTHHoth Therapeutics2.9343 of 5 stars$2.08+7.0%$4.00+92.8%+89.7%$27.52MN/A-1.944RNTXRein Therapeutics2.4665 of 5 stars$1.18flat$10.00+747.5%N/A$27.51MN/A-0.449High Trading VolumeLEXXLexaria Bioscience3.6495 of 5 stars$1.34-0.7%$4.00+198.5%-65.2%$26.21M$460K-2.007News CoverageGap DownMTVAMetaVia2.5122 of 5 stars$1.06+2.9%$7.50+607.5%N/A$25.65MN/A0.008Gap DownRLYBRallybio2.9594 of 5 stars$0.61+0.3%$5.00+718.3%-50.2%$25.53M$640K-0.6540Gap Up Related Companies and Tools Related Companies Lunai Bioworks Alternatives Tenax Therapeutics Alternatives Kezar Life Sciences Alternatives Dare Bioscience Alternatives Cadrenal Therapeutics Alternatives Hoth Therapeutics Alternatives Rein Therapeutics Alternatives Lexaria Bioscience Alternatives MetaVia Alternatives Rallybio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
